CUTISS vs Emulate
Side-by-side comparison of AI visibility scores, market position, and capabilities
CUTISS is a Swiss biotech developing personalized dermo-epidermal skin grafts from patient cells for large skin defect treatment; denovoSkin product reduces reliance on painful autografts; raised CHF 30M+ in funding;
About
CUTISS is a Swiss clinical-stage biotechnology company founded in 2017 as a spin-off from the University Children's Hospital Zurich, focused on developing personalized bioengineered skin grafts for patients with large skin defects caused by severe burns, rare congenital skin diseases, and traumatic wounds. The company's lead product, denovoSkin, is a dermo-epidermal skin graft manufactured by combining a small biopsy of a patient's own skin cells with a proprietary hydrogel scaffold — which is then cultured to grow a full-thickness skin equivalent containing both the dermis (dermal layer) and epidermis (outer layer). Because the graft uses the patient's own cells, it avoids immune rejection without the need for immunosuppression.
Pioneering organ-on-chip platform installed in 150+ labs including 17 of the top 25 biopharma companies; launched AVA™ high-throughput 96-chip system in 2025 and holds the only FDA ISTAND-accepted DILI Organ-Chip.
About
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the microstructure and function of human organs. Founded in 2013 as a spin-out from the Wyss Institute at Harvard University, Emulate's chips model the liver, intestine, lung, kidney, brain, and other organ systems with a fidelity that animal models and traditional cell culture cannot match. The technology was originally developed to reduce drug development attrition rates caused by poor translation from animal studies to human clinical outcomes.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.